Table 5.
Inter-cohort comparison of type-specific substitution mutations across all TP53 exons
| Mutation | CA-SMK1 | NC-SMK2 | NC-NON3 | NC-TOT4 |
|---|---|---|---|---|
| C > A | 17 (2.0 × 10−3)* | 1 (1.2 × 10−4) | 0 | 1 (1.2 × 10−4) |
| C > G | 1 (1.2 × 10−4) | 1 (1.2 × 10− 4) | 0 | 1 (1.2 × 10− 4) |
| C > T | 27 (3.2 × 10−3)*** | 1 (1.2 × 10− 4) | 1 (1.2 × 10− 4) | 2 (2.4 × 10− 4) |
| T > A | 3 (3.6 × 10− 4) | 0 | 0 | 0 |
| T > C | 9 (1.1 × 10− 4)* | 0 | 0 | 0 |
| T > G | 0 | 0 | 0 | 0 |
1CA-SMK; Cancer subject, present or past smoker. 2NC-SMK; Non-Cancer subject, present or past smoker. 3NC-NON; Non-Cancer subject, never smoker. 4NC-TOT; All Non-Cancer subjects, smokers and non-smokers
*p < 0.05; **p < 0.01; ***p < 0.005
Mutation number with prevalence in parentheses (mutations/target bp/subject) for each substitution type. Mutations were called as described in Methods section, after testing for significance of mutation VAF above background and using a VAF of 0.05% as a minimum threshold